Unknown

Dataset Information

Erythropoietin prevents necrotizing enterocolitis in very preterm infants: a randomized controlled trial.


ABSTRACT:

Background

Necrotizing enterocolitis (NEC) is one of the most severe complications in very preterm infants, but there are currently no accepted methods to prevent NEC. Studies have shown that erythropoietin (EPO) has the potential to prevent NEC or improve outcomes of preterm NEC. This study aimed to determine whether recombinant human EPO (rhEPO) could protect against NEC in very preterm infants.

Methods

The study was a prospective randomized clinical trial performed among four NICU centers. A total of 1327 preterm infants with gestational age ≤ 32 weeks were admitted to the centers, and 42 infants were excluded leaving 1285 eligible infants to be randomized to the rhEPO or control group. Infants in the rhEPO group were given 500 IU/kg rhEPO intravenously every other day fo

SUBMITTER: Wang Y 

PROVIDER: S-EPMC7414749 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature